Ftse Mib
34.276,02
-1,14%
DAX
18.405,64
-1,10%
S&P 500
5.291,34
0,15%
NASDAQ
16.857,05
0,17%
Bitcoin
70.542,65
-0,03%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Purple Biotech Ltd (PPBT) Purple Biotech Ltd (PPBT) Notizie

PPBT

Purple Biotech (PPBT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PPBT
DataOraFonteTitoloSimboloCompagnia
04/06/202422:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PPBTPurple Biotech Ltd
01/06/202414:00GlobeNewswire Inc.Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerNASDAQ:PPBTPurple Biotech Ltd
21/05/202413:30GlobeNewswire Inc.Purple Biotech Reports First Quarter 2024 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
25/04/202413:00GlobeNewswire Inc.Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingNASDAQ:PPBTPurple Biotech Ltd
28/03/202412:00GlobeNewswire Inc.Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024NASDAQ:PPBTPurple Biotech Ltd
14/03/202412:30GlobeNewswire Inc.Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyNASDAQ:PPBTPurple Biotech Ltd
05/03/202422:00Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:PPBTPurple Biotech Ltd
05/03/202413:55GlobeNewswire Inc.Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
27/02/202413:00GlobeNewswire Inc.Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024NASDAQ:PPBTPurple Biotech Ltd
13/02/202413:00GlobeNewswire Inc.Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 TrialNASDAQ:PPBTPurple Biotech Ltd
01/02/202413:30GlobeNewswire Inc.Purple Biotech Reaches Recommended Phase 2 Dose for NT219NASDAQ:PPBTPurple Biotech Ltd
20/12/202314:05GlobeNewswire Inc.Purple Biotech Appoints Dr. Yael Margolin to its Board of DirectorsNASDAQ:PPBTPurple Biotech Ltd
14/12/202312:50GlobeNewswire Inc.Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer TrialNASDAQ:PPBTPurple Biotech Ltd
21/11/202312:50GlobeNewswire Inc.Purple Biotech Reports Third Quarter 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
15/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PPBTPurple Biotech Ltd
14/11/202322:13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PPBTPurple Biotech Ltd
13/11/202322:11Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:PPBTPurple Biotech Ltd
02/11/202312:00GlobeNewswire Inc.Purple Biotech Fortifies NT219 Patent ProtectionNASDAQ:PPBTPurple Biotech Ltd
31/10/202321:30Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:PPBTPurple Biotech Ltd
30/10/202321:30Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:PPBTPurple Biotech Ltd
19/10/202321:55GlobeNewswire Inc.Purple Biotech Announces Closing of $5 Million Registered Direct OfferingNASDAQ:PPBTPurple Biotech Ltd
19/10/202316:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PPBTPurple Biotech Ltd
17/10/202314:00GlobeNewswire Inc.Purple Biotech Announces $5 Million Registered Direct OfferingNASDAQ:PPBTPurple Biotech Ltd
06/10/202313:50GlobeNewswire Inc.Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of ActionNASDAQ:PPBTPurple Biotech Ltd
03/10/202313:50GlobeNewswire Inc.Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck CancerNASDAQ:PPBTPurple Biotech Ltd
21/09/202314:00GlobeNewswire Inc.Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023NASDAQ:PPBTPurple Biotech Ltd
22/08/202315:29GlobeNewswire Inc.Purple Biotech Reports Second Quarter 2023 Financial ResultsNASDAQ:PPBTPurple Biotech Ltd
11/07/202314:15GlobeNewswire Inc.Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer PatientsNASDAQ:PPBTPurple Biotech Ltd
20/06/202314:01Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:PPBTPurple Biotech Ltd
15/06/202322:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PPBTPurple Biotech Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PPBT

La tua Cronologia

BIT
P1GLD9
BNP Paribas Issuance
LSE
64ZM
Lile Fin3.179%r
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network